Effects of serotonin (5-HT)2 receptor ligands on depression-like behavior during nicotine withdrawal

Zaniewska, Magdalena; McCreary, Andrew C.; Wydra, Karolina; Filip, Małgorzata

doi:10.1016/j.neuropharm.2010.02.006

Cited by 61 publications

(54 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In rodents, treatment with medications commonly used in augmentative regimens enhances the response of antidepressants in the FST (Cryan et al, 2005;Detke et al, 1995b;Haddjeri et al, 2004;Moser and Sanger, 1999;Wieland and Lucki, 1990;Zaniewska et al, 2010). In our study, none of the drugs used for augmentation induced a significant antidepressant-like response in this model (although a 10% nonsignificant decrease in immobility was observed in animals given buspirone).…”

Section: Discussionmentioning

confidence: 40%

Augmentative therapies do not potentiate the antidepressant-like effects of deep brain stimulation in rats

Laver

Diwan

Nóbrega

et al. 2014

Journal of Affective Disorders

View full text Add to dashboard Cite

Background-Clinical trials have shown promising results with the use of subcallosal cingulate gyrus deep brain stimulation (DBS) for treatment-resistant depression. However, strategies to manage patients who do not respond to this therapy have not been explored in detail. In rats, DBS in the ventromedial prefrontal cortex (vmPFC) induces a significant antidepressant-like response in the forced swim test (FST). We have used this test to investigate potential interactions between DBS and clinically used augmentative regimens.Methods-Rats undergoing the FST were treated with vmPFC DBS along with different augmentative drugs, namely buspirone, risperidone and pindolol. Locomotor activity was tested in an open field.Results-DBS induced a significant reduction in immobility scores as compared to saline treated controls. These antidepressant-like effects, however, were not potentiated by the co-administration of buspirone, risperidone or pindolol.Limitations-Despite having good predictive validity, animal models are limited from a translational perspective.Conclusions-Our results indicate that that the antidepressant-like effects of vmPFC DBS in the FST are not enhanced by augmentative therapies.

show abstract

Section: Discussionmentioning

confidence: 40%

Augmentative therapies do not potentiate the antidepressant-like effects of deep brain stimulation in rats

Laver

Diwan

Nóbrega

et al. 2014

Journal of Affective Disorders

View full text Add to dashboard Cite

show abstract

“…5-HT 2A receptor antagonism could facilitate the cessation of tobacco smoking by relieving nicotine-withdrawal symptoms (Zaniewska et al, 2010). Some studies have indicated that the T allele of the 5-HT 2A T102C polymorphism (and, by analogy, the A allele at -1438 in the regulatory region of 5-HT 2A ) is linked to higher 5-HT 2A receptor binding, but lower receptor binding related to the C allele, based on postmortem brain samples (Turecki et al, 1999).…”

Section: Discussionmentioning

confidence: 99%

Association of HTTLPR and 5-HT2A T102C polymorphisms with smoking characteristics and anthropometric profiles of Thai males

Suriyaprom¹,

Phonrat²,

Chuensumran³

et al. 2012

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Nicotine increases serotonin release in the brain. Gene polymorphisms in the serotonergic system have been suggested to be associated with smoking behavior. We investigated a possible association between two polymorphisms in the serotonergic system -HTTLPR of a serotonin transporter gene and 5-HT 2A at position T102C -with biochemical and anthropometric parameters, and with cigarette smoking in an investigation of 200 smokers and 111 non-smokers. The two polymorphisms, HTTLPR and 5-HT 2A at position T102C, were genotyped by PCR-RFLP. They were not significantly associated with smoking status in these Thai males. Among the smokers, thiocyanate concentrations and quantity of cigarettes smoked (cigarette pack-years) were significantly higher for individuals with LL/LS genotypes than SS HTTLPR and 5-HT 2A T102C polymorphisms and smoking genotypes of 5-HTTLPR (all P < 0.05), whereas "age at starting smoking" and "duration of smoking" were not significantly different between these two genotypes. Moreover, anthropometric variables, comprising triceps skinfold thickness, arm circumference, waist circumference, hip circumference, and waist-to-hip ratio, were significantly higher for the CC/TC genotypes of 5-HT 2A than the TT genotype (all P < 0.05), except for body mass index. HTTLPR and 5-HT 2A T102C polymorphisms were not significantly associated with smoking status among Thai males; however, the HTTLPR polymorphism among smokers appears to be an indicator of increased smoking intensity consisting of cigarette packyears and thiocyanate concentrations. The 5-HT 2A T102C polymorphism plays a role in the anthropometric profiles, triceps skinfold thickness, arm circumference, waist circumference, hip circumference, and waist-to-hip ratio, but not smoking status in Thai subjects.

show abstract

“…The cessation of chronic nicotine use can produce aversive effects, including both motivational and somatic withdrawal symptoms such as nicotine craving, anxiety, reduced concentration, irritability, depressed mood and an increased appetite [ 148 ]. These withdrawal effects are considered to be the main factors in the maintenance of the tobacco habit in human smokers.…”

Section: -Ht 2c Receptorsmentioning

confidence: 99%

Role of Central Serotonin Receptors in Nicotine Addiction

Pierucci

Chambers

Partridge

et al. 2014

Nicotinic Receptors

View full text Add to dashboard Cite

Regulation of normal or abnormal behaviour is critically controlled by the central serotonergic systems. Recent evidence has suggested that serotonin (5-HT) neurotransmission dysfunction contributes to a variety of pathological conditions, including depression, anxiety, schizophrenia and Parkinson's disorders. There is also a great amount of evidence indicating that 5-HT signalling may affect the reinforcing properties of drugs of abuse by the interaction and modulation of dopamine (DA) function. This chapter is focused on one of the more addictive drugs, nicotine. It is widely recognised that the effects of nicotine are strongly associated with the stimulatory action it exhibits on mesolimbic DAergic function. We outline the role of 5-HT and its plethora of receptors, focusing on 5-HT 2 subtypes with relation to their involvement in the neurobiology of nicotine addiction. We also explore the novel pharmacological approaches using 5-HT agents for the treatment of nicotine dependence. Compelling evidence shows that 5-HT 2C receptor agonists may be possible therapeutic targets for smoking cessation, although further investigation is required.

show abstract

Effects of serotonin (5-HT)2 receptor ligands on depression-like behavior during nicotine withdrawal

Cited by 61 publications

References 41 publications

Augmentative therapies do not potentiate the antidepressant-like effects of deep brain stimulation in rats

Augmentative therapies do not potentiate the antidepressant-like effects of deep brain stimulation in rats

Association of HTTLPR and 5-HT2A T102C polymorphisms with smoking characteristics and anthropometric profiles of Thai males

Role of Central Serotonin Receptors in Nicotine Addiction

Contact Info

Product

Resources

About